Engineered immune cells take on tough leukemias
NCT ID NCT06364423
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 2 times
Summary
This trial tests a therapy where a person's own immune cells are modified to attack cancer cells carrying a protein called CD19. It is for adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or B-cell acute lymphoblastic leukemia that has not responded to standard treatments. Participants receive the modified cells after a short course of chemotherapy, and are monitored closely for safety and response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-CD19 CAR T cells (modified immune cells)
- What this could lead to
- If successful, this could offer a new treatment option for people with hard-to-treat B-cell blood cancers.
- What could go wrong
- This is an early-phase trial, so the treatment may not work for everyone and could cause serious side effects like immune reactions or infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a diet and exercise program help childhood leukemia survivors live healthier?
- Could bone marrow from deceased donors cure blood cancers?
- New biologic MK-1045 targets Hard-to-Treat blood cancers
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers